icon-folder.gif   Conference Reports for NATAP  
  65th Annual Meeting of the
American Association for the
Study of Liver Diseases
Boston, MA Nov 7-11 2014
Back grey_arrow_rt.gif
Burden of Side Effects Associated with Treatment of Hepatitis C
  Reported by Jules Levin
AASLD 2014 Boston Nov 8-11
Buikema AR, MPH1; Rosenblatt LC, MD, MPH2; Liu F, MS, MD1; Gorsh B, PharmD2; White JC, DPM, MS1; Sill BE, PharmD, MS2 1Optum, Eden Prairie, MN; 2Bristol Myers-Squibb Company, Plainsboro, NJ
"Until 2011, the standard of care for chronic HCV infection was a "dual therapy" combination of pegylated interferon alfa-2a or alfa-2b (PEG) and ribavirin (RBV). This changed with the 2011 approval of the first two direct-acting antiviral (DAA) medications, the oral protease inhibitors (PIs), boceprevir (BOC) and telaprevir (TVR), which are used in combination with PEG and RBV as "triple therapy".4 ......
Common symptoms of HCV infection and treatment-related side effects of dual and triple therapies include: fatigue, depression, anemia, thrombocytopenia, bone marrow suppression, and rash.5-8 .......
The purpose of this study was to estimate the current costs of HCV treatment and treatment-associated side effects including rash, anemia, neutropenia, thrombocytopenia, depression, anxiety, fatigue and gastrointestinal (GI) disorders, using administrative claims data."